OnKure Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — |
| Operating income | -$63.0M | -$54.4M | -$36.9M | -$53.8M | -$39.8M |
| Operating expenses | $63.0M | $54.4M | $36.9M | $53.8M | $39.8M |
| Cash from operations | -$51.8M | -$51.1M | -$34.5M | -$47.4M | -$38.0M |
| Capital expenditure | $46,000 | $52,000 | $246,000 | $346,000 | $198,000 |
| Free cash flow | -$51.9M | -$51.2M | -$34.8M | -$47.7M | -$38.2M |
| Share repurchases | — | — | $4.4M | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $62.1M | $114.9M | $35.7M | $108.2M | $154.0M |
| Total liabilities | $5.9M | $11.1M | $7.8M | $8.2M | $6.8M |
Shares outstanding 40.4M · Free float 62.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.